Use of probiotic-containing foods and probiotic supplements is increasing; however, few studies document safety and tolerability in conjunction with defined clinical end points. This paper reports the effects of 150 days of supplementation with either a single-(Bifidobacterium animalis subsp. lactis Bl-04) or a double-strain (Lactobacillus acidophilus NCFM and Bifidobacterium animalis subsp. lactis Bi-07) probiotic on routine haematology and clinical chemistry measures in healthy active adults. Pre-to post-intervention changes in laboratory measures were determined and compared between supplement and placebo groups. Overall there were few differences in routine haematology and clinical chemistry measures between supplement and placebo groups post-intervention. Exceptions included plasma calcium (P = 0.03) and urea (P = 0.015); however, observed changes were small and within assay-specific laboratory reference ranges. These data provide evidence supporting the use of these probiotic supplements over a period of 5 months in healthy active adults without obvious safety or tolerability issues.
INTRODUCTION
Probiotics are viable microorganisms capable of surviving transit through the gastrointestinal tract and having the potential to exert positive health effects, including modulation of intestinal microflora, enhancement of immune function, improved gastrointestinal health, and protection against infectious illness.
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While probiotic use is increasing and generally appears to be well tolerated, few intervention studies have clearly documented safety and tolerability in conjunction with defined clinical end points. Growing demand for probiotic supplements has led to increasing focus on the adequacy of regulatory systems to address issues of safety. 4 Not all available products have been the subject of rigorous clinical study and when marketed as functional foods are not subject to the same regulatory requirements as other classes of non-prescription supplements. Given the range of formulations and varying dosages available, this information may be important.
This paper reports on assessment of safety and tolerability in a population of healthy active adults participating in a 150-day probiotic supplement study.
MATERIALS AND METHODS

Study design
Data for this analysis were collected as part of a 150-day randomised double-blind placebo-controlled trial to examine the effect of probiotic supplementation on respiratory and gastrointestinal illness in adults aged 18-60 years, physically active (43 h of physical activity per week for the previous 3 months) and in general good health. 5 Supplements were (i) Bifidobacterium animalis subsp. lactis Bl-04 (B. lactis Bl-04; Danisco Inc, Madison, WI, USA) at a total dose of 2.0 × 10 9 colony-forming units (CFU) per day, (ii) Lactobacillus acidophilus NCFM (L. acidophilus NCFM) and Bifidobacterium animalis subsp. lactis Bi-07 (B. lactis Bi-07; Danisco Inc) at a total dose of 1.0 × 10 10 CFU (5 × 10 9 CFU of each strain) and (iii) placebo; all were prepared in a 1 g sucrose-base and were identical in appearance and taste. Blood samples were collected at day 0 and day 150 for measurement of routine haematology and clinical chemistry measures.
The Griffith University Human Research Ethics Committee and the Australian Institute of Sport Human Research Ethics Committee provided ethical approval for this study; all study procedures were carried out in accordance with the Declaration of Helsinki, and all subjects provided written informed consent.
Laboratory measures Blood samples were collected into ethylenediaminetetraacetic acid and serum separator tubes. Serum was separated by centrifugation within 4h of collection for storage at − 80°C until analysis.
Routine haematology comprised a full blood count with white cell differential performed using a Sysmex XT-2000i Automated Haematology Analyser (Sysmex Corporation, Kobe, Japan). Routine chemistry analyses were performed on an Abbott ci8200 or ci16200 analyser (Abbott Park, IL, USA) in an ISO15189 accredited laboratory. The analytes tested were sodium, potassium, chloride, magnesium, total calcium, phosphate, alanine 1 transaminase, aspartate aminotransferase, alkaline phosphatase, lactate dehydrogenase, total bilirubin, urea, bicarbonate, uric acid, total protein, albumin, total cholesterol, triglycerides, high-density lipoprotein, insulin, thyroid-stimulating hormone and C-reactive protein. Assay performance over the analysis period resulted in coefficients of variation ranging from 0.8 to 5.3% for kidney function tests, 1.1 to 3.4% for liver function tests, and o 8% for cardiac markers, o 3.5% for lipid analysis and o 4.5% for specific proteins.
Statistical analysis Pre-to post-intervention changes in all laboratory measures were determined. Change scores were compared between the two supplement groups and the placebo group using a one-way analysis of variance. Analyses were performed using SPSS Statistics v21 (IBM Corporation, Armonk, NY, USA). Statistical significance was accepted at P o0.05.
RESULTS
Data pertain to 125 participants from the intervention trial: 39 participants from the single-strain Bl-04 supplement group (SS), 41 participants from dual-strain NCMF and Bi-07 supplement group (DS) and 45 participants from the placebo group (PL). Groups were matched on key demographic characteristics (Table 1) .
Supplement use was generally well tolerated; no clinically adverse events were reported in these participants. Adverse event reporting for the full cohort has been reported previously and included one participant (0.2%) withdrawing for headaches (DS) and three participants (0.6%; PL n = 1, SS n = 2) withdrawing because of uncomfortable gastrointestinal symptoms after the onset of supplementation. 5 Comparison of the pre-to post-intervention changes revealed few differences between groups (Table 2 ). Exceptions included plasma calcium (decrease post-intervention in the PL group; Probiotic supplement safety AJ Cox et al P = 0.002) and urea (decrease post intervention in the DS group; P = 0.05). Statistically significant changes were observed in many other analytes post-intervention (Table 2) . However, these changes were small, within established assay-specific laboratory reference ranges, and frequently observed in both supplement and placebo groups. These changes were not considered to be a result of the probiotic supplementation.
DISCUSSION
The current analysis examined the effects of 5 months of probiotic supplementation on routine haematology and clinical chemistry measures to provide an insight into supplement safety in healthy active adults. The supplements were well tolerated by participants and resulted in a reduced risk for upper respiratory illness. 5 There were some small changes observed in the examined measures pre-to post-intervention. However, these were within the established reference ranges and largely similar between supplement and placebo groups. Overall these findings, in conjunction with the low reported rate of adverse events, suggest the safe use of this form of probiotic supplement in healthy active adults over a period of 5 months.
Simple explanations, independent of probiotic supplementation, may account for the small number of significant differences observed between groups pre-to post-intervention. For calcium, a change in hydration status in the placebo group post intervention may underpin the observed decrease in calcium concentration; similar patterns were also noted for other electrolytes, further supporting the feasibility of this explanation. For urea, a change in the dietary protein content among the DS group in the period preceding the post-intervention sample collection may have contributed to the decrease observed for the DS group, particularly given that strict dietary control (with the exception of probiotic-containing foods) was not an element of the study design. Despite these statistically significant findings, these differences were not considered to be clinically relevant.
Routine haematology and clinical chemistry measures have been used previously for the purposes of safety monitoring in the context of probiotic supplementation. Ringel-Kulka et al. 6 have previously reported minimal impact of the B. lactis Bi-07 strain at a dose of 2 × 10 11 CFU daily over 8 weeks on haematology measures and indices of liver and kidney function in 60 patients with functional bowel disorders. The findings described in the current report extend this earlier study by showing similar safety and tolerability over a longer supplementation period in healthy active individuals. Obviously different formulations and dosages may produce varying results and data from other intervention studies are required to further establish the safety profile of probiotic use. Indeed, in the absence of clear regulatory requirements, reporting of safety and tolerability information in conjunction with defined clinical end points will provide consumers with additional information to consider when making choices about use of probiotic supplements.
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